Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders

Human Psychopharmacology

Volumn 28, Issue 6, 2013, Pages 538-543

  Nandhra, Harpal Singh ^a   Murphy, Catherine Louise ^b   Sule, Akeem ^c  

^a University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

anxiety; memory; pharmacotherapy

Indexed keywords

ADRENALIN; CYCLOSERINE; FLUOXETINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; PROPRANOLOL; RILUZOLE;

ANXIETY DISORDER; COGNITION; DRUG EFFECT; DRUG MECHANISM; HUMAN; MEMORY; MEMORY CONSOLIDATION; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; COGNITION; DRUG DESIGN; HUMANS; MEMORY; MOLECULAR TARGETED THERAPY; N-METHYLASPARTATE; RECEPTORS, ADRENERGIC, BETA;

EID: 84887237378     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2348     Document Type: Review

References (46)

1. Aboujaoude E, Barry JJ, Gamel N,. 2009. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29 (1): 51-55
2. Amorapanth P, LeDoux JE, Nader K,. 2000. Different lateral amygdala outputs mediate reactions and actions elicited by a fear arousing stimulus. Nat Neurosci 3 (1): 74-79. (Pubitemid 30126351)
3. Baldwin DS, Anderson IM, Nutt DJ, et al,. 2005. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. British Association for Psychopharmacology. J Psychopharmacol 19 (6): 567-596. (Pubitemid 41578819)
4. Bandelow B, Zohar J, Hollander E, et al,. 2008. World federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9 (4): 248-312.
5. Blair HT, Sotres-Bayon F, Moita MA, Ledoux JE,. 2005. The lateral amygdala processes the value of conditioned and unconditioned aversive stimuli. Neuroscience 133 (2): 561-569. (Pubitemid 40726222)
6. Cavazzuti E, Bertolini A, Vergoni AV, et al,. 1999. l-Sulpiride, at a low, non-neuroleptic dose, prevents conditioned fear stress-induced freezing behaviour in rats. Psychopharmacology (Berl) 142: 20-23. (Pubitemid 29189990)
7. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S,. 2005. Glutamergic dysfunction in OCD, Neuropsychopharmacology 30 (9): 1735-1740.
8. Coric V, Taskiran S, Pittenger C, et al,. 2005. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58 (5): 424-428. (Pubitemid 41219711)
9. Davis M,. 1994. The role of the amygdala in emotional learning. Int Rev Neurobiol 36: 225-266. (Pubitemid 2142764)
10. De Girolamo G, Alonso J, Vilagut G,. 2006. The ESEMeD-WMH project: strengthening epidemiological research in Europe through the study of variation in prevalence estimates. Epidemiol Psichiatr Soc 15 (3): 167-173. (Pubitemid 44784457)
11. De Kleine RA, Hendriks G-J, Kusters WJC, Broekman TG, van Minnen A,. 2012. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psych 71 (11): 962-968.
12. Diebic J, Ledoux JE,. 2004. Disruption of reconsolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience 129: 267-732.
13. Feusner JD, Kerwin L, Saxena S, Bystritsky A,. 2009. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 42 (1): 81-93.
14. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E,. 2000. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder. JAMA 283 (23): 3082-3088. (Pubitemid 30399718)
15. Glannon W,. 2006. Psychopharmacology and memory. J Med Ethics 32 (2): 74-78. (Pubitemid 43230576)
16. Goosens KA, Maren S,. 2001. Contextual and auditory fear conditioning are mediated by the lateral, basal, and central amygdaloidal nuclei in rats. Learn Mem 8 (3): 148-155. (Pubitemid 32552863)
17. Graham BM, Langton JM, Richardson R,. 2011. Pharmacological enhancement of fear reduction: preclinical models. Br J Pharmacol 164: 1230-1247.
18. Grant P, Lougee L, Hirschtritt M, Swedo SE,. 2007. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17 (6): 761-767. (Pubitemid 351158597)
19. Hofmann SG, Meuret AE, Smits JA, et al,. 2006. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63 (3): 298-304. (Pubitemid 43345354)
20. Kardos J,. 1999. Recent advances in GABA research. Neurochem Int 34 (5): 353-358. Review. (Pubitemid 29240631)
21. Kessal K, Deschaux O, Chessel A, Xu L, Moreau JL, Garcia R,. 2006. Fluoxetine reverses stress-induced fimbria-prefrontal long-term potentiation facilitation. Neuroreport 17 (3): 319-322.
22. Kessler RC, McGonagle KA, Zhao S, et al,. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results: from the national comorbidity survey. Arch Gen Psychiatry 51 (1): 8-19. (Pubitemid 24028993)
23. Kushner MG, Kim SW, Donahue C, et al,. 2007. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 62 (8): 835-838. Epub. (Pubitemid 47488217)
24. Ledgerwood L, Richardson R, Cranney J,. 2005. D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 57 (8): 841-847. (Pubitemid 40488352)
25. LeDoux JE,. 2000. Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
26. Litz BT, Salters-Pedneault K, Steenkamp MM, et al,. 2012. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 46 (9): 1184-1190.
27. McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH,. 2009. The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res 30 (1): 92-97.
28. Maren S, Aharonov G, Stote DL, Fanselow MS,. 1996. N-methyl-D-aspartate receptors in the basolateral amygdala are required for both acquisition and expression of conditional fear in rats. Behav Neurosci 110 (6): 1365-1374. (Pubitemid 27009199)
29. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM,. 2005. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162: 2379-2381. (Pubitemid 41740219)
30. Mathew SJ, Price RB, Mao X, et al,. 2008. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry 63 (9): 891-898. Epub 2007 Oct 29. (Pubitemid 351458451)
31. Myers KM, Davis M,. 2007. Mechanisms of fear extinction. Mol Psychiatry 12 (2): 120-150. Epub. (Pubitemid 46160979)
32. Norberg MM, Krystal JH, Tolin DF,. 2008. Review. a meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psych 63: 1118-1126.
33. Phelps E,. 2004. Human emotion and memory: interactions of the amygdala and hippocampal complex. Curr Opin Neurobiol 14 (2): 198-202. (Pubitemid 38479937)
34. Pitman RK, Sanders KM, Zusman RM, et al,. 2002. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51 (2): 189-192. (Pubitemid 34127909)
35. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G,. 2008. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22 (9): 761-786.
36. Pollack MH, Zaninelli R, Goddard A, et al,. 2001. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62 (5): 350-357. (Pubitemid 32545557)
37. Poyurovsky M, Weizman R, Weizman A, et al,. 2005. Memantine for treatment-resistant OCD. Am J Psychiatry 162: 2191-2192.
38. Przybyslawski J, Roullet P, Sara SJ,. 1999. Attenuation of emotional and non emotional memories after their reactivation: role of beta adrenergic receptors. J Neurosci 19 (15): 6623-6628. (Pubitemid 29347461)
39. Sheehan DV, Meyers AL, Prakash A, et al,. 2008. The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. Curr Med Res Opin 24 (9): 2457-2466. Epub.
40. Taylor F, Cahill LJ,. 2002. Propranolol for re-emergent posttraumatic stress disorder following an event of retraumatization: a case study. Trauma Stress 15 (5): 433-437.
41. Wald R, Dodman N, Shuster L,. 2009. The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder. Exp Clin Psychopharmacol 17 (3): 191-197.
42. Wallace KJ, Rosen JB,. 2001. Neurotoxic lesions of the lateral nucleus of the amygdala decrease conditioned fear but not unconditioned fear of a predator odor: comparison with electrolytic lesions. J Neurosci 21 (10): 3619-3627. (Pubitemid 32422826)
43. Walker DL, Ressler KJ, Lu KT, Davis M,. 2002. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear potentiated startle in rats. J Neurosci 22 (6): 2343-2351. (Pubitemid 35386533)
44. Wilhelm S, Buhlmann U, Tolin DF, et al,. 2008. Augmentation of behaviour therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 165 (3): 335-341. (Pubitemid 351704489)
45. Wittchen HU,. 2002. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16 (4): 162-171.
46. Wittchen HU, Zhao S, Kessler RC, Eaton WW,. 1994. Survey. Arch Gen Psychiatry 51 (5): 355-364.